Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC

Wolfgang Miesbach; Fariba Baghaei; Ana Boban; Pratima Chowdary; Michiel Coppens; Daniel P. Hart; Victor Jimenez-Yuste; Robert Klamroth; Mike Makris; Declan Noone; Flora Peyvandi

doi:10.1111/hae.14546

Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC

Wolfgang Miesbach^*
, Fariba Baghaei
, Ana Boban
, Pratima Chowdary
, Michiel Coppens
, Daniel P. Hart
, Victor Jimenez-Yuste
, Robert Klamroth
, Mike Makris
, Declan Noone
, Flora Peyvandi

^*Corresponding author for this work

Goethe University Frankfurt
University of Gothenburg
University of Zagreb
Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust and University College London, London, UK
Amsterdam UMC
Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK
Universidad Autónoma de Madrid
Vivantes Netzwerk für Gesundheit GmbH
University of Sheffield
European Haemopilia Consortium
IRCCS Fondazione Ca'Granda – Ospedale Maggiore Policlinico - Milano
University of Milan

Research output: Contribution to journal › Comment/Letter to the editor › Academic

46 Downloads (Pure)

Original language	English
Pages (from-to)	e86-e88
Journal	Haemophilia
Volume	28
Issue number	3
Early online date	2022
DOIs	https://doi.org/10.1111/hae.14546
Publication status	Published - May 2022

Access to Document

10.1111/hae.14546

Gene-therapy-of-hemophilia.pdfFinal published version, 136 KBLicence: CC BY

Cite this

@article{24a6c8d909c34c1d869405d21a8052d0,

title = "Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC",

author = "Wolfgang Miesbach and Fariba Baghaei and Ana Boban and Pratima Chowdary and Michiel Coppens and Hart, \{Daniel P.\} and Victor Jimenez-Yuste and Robert Klamroth and Mike Makris and Declan Noone and Flora Peyvandi",

note = "Funding Information: Wolfgang Miesbach: Bayer, Biomarin, Biotest, CSL Behring, Chugai, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda/Shire, uniQure. Ana Boban: Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Takeda. Fariba Baghaei: Bayer, Octapharma, Pfizer, Novo Nordisk, Shire/Takeda, Roche, BioMarin, uniQure, Sobi. Pratima Chowdary: advisory boards for Bayer, Boehringer Ingelheim, CSL Behring, Chugai, Freeline, NovoNordisk, Pfizer, Roche, Sanofi, Spark, Sobi and Takeda; and has received research funding from Bayer, CSL Behring, Freeline, Novo Nordisk, Pfizer, SOBI and Takeda. Michiel Coppens: Research support: Bayer, CSL Behring, Roche, Sanquin Blood Supply, UniQure; Consultancy or lecturing fees: Bayer, CSL Behring, Medcon International, MEDtalks, NovoNordisk, Pfizer, Sobi. Daniel P. Hart: Bayer, Biomarin, Biotest, CSL Behring, Grifols, NovoNordisk, Octapharma, Pfizer, Roche, Sanofi, Sobi, Spark, Takeda, UniQure. Victor Jimenez‐Yuste: Bayer, Biomarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda/Shire. Robert Klamroth: Research Funding and Consultancy: Bayer, Biomarin, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche/Chugai, Sanofi, SOBI, Takeda/Shire, uniQure. Mike Makris participated in advisory boards run by Freeline, Spark Therapeutics and NovoNordisk. Flora Peyvandi: speaker at educational symposia organized by Roche, Sanofi, Sobi, Takeda. Member of Advisory Board of Roche, Sanofi, Sobi, Takeda.",

year = "2022",

month = may,

doi = "10.1111/hae.14546",

language = "English",

volume = "28",

pages = "e86--e88",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "Wiley Blackwell",

number = "3",

}

TY - JOUR

T1 - Gene therapy of hemophilia

T2 - Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC

AU - Miesbach, Wolfgang

AU - Baghaei, Fariba

AU - Boban, Ana

AU - Chowdary, Pratima

AU - Coppens, Michiel

AU - Hart, Daniel P.

AU - Jimenez-Yuste, Victor

AU - Klamroth, Robert

AU - Makris, Mike

AU - Noone, Declan

AU - Peyvandi, Flora

N1 - Funding Information: Wolfgang Miesbach: Bayer, Biomarin, Biotest, CSL Behring, Chugai, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda/Shire, uniQure. Ana Boban: Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Takeda. Fariba Baghaei: Bayer, Octapharma, Pfizer, Novo Nordisk, Shire/Takeda, Roche, BioMarin, uniQure, Sobi. Pratima Chowdary: advisory boards for Bayer, Boehringer Ingelheim, CSL Behring, Chugai, Freeline, NovoNordisk, Pfizer, Roche, Sanofi, Spark, Sobi and Takeda; and has received research funding from Bayer, CSL Behring, Freeline, Novo Nordisk, Pfizer, SOBI and Takeda. Michiel Coppens: Research support: Bayer, CSL Behring, Roche, Sanquin Blood Supply, UniQure; Consultancy or lecturing fees: Bayer, CSL Behring, Medcon International, MEDtalks, NovoNordisk, Pfizer, Sobi. Daniel P. Hart: Bayer, Biomarin, Biotest, CSL Behring, Grifols, NovoNordisk, Octapharma, Pfizer, Roche, Sanofi, Sobi, Spark, Takeda, UniQure. Victor Jimenez‐Yuste: Bayer, Biomarin, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda/Shire. Robert Klamroth: Research Funding and Consultancy: Bayer, Biomarin, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche/Chugai, Sanofi, SOBI, Takeda/Shire, uniQure. Mike Makris participated in advisory boards run by Freeline, Spark Therapeutics and NovoNordisk. Flora Peyvandi: speaker at educational symposia organized by Roche, Sanofi, Sobi, Takeda. Member of Advisory Board of Roche, Sanofi, Sobi, Takeda.

PY - 2022/5

Y1 - 2022/5

UR - https://www.scopus.com/pages/publications/85125884512

U2 - 10.1111/hae.14546

DO - 10.1111/hae.14546

M3 - Comment/Letter to the editor

C2 - 35263819

SN - 1351-8216

VL - 28

SP - e86-e88

JO - Haemophilia

JF - Haemophilia

IS - 3

ER -

Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC

Access to Document

Other files and links

Cite this